Newswire (Published: Thursday, April 4, 2019, Received: Thursday, April 4, 2019, 3:59:16 PM CDT)

Word Count: 388

2019 APR 04 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- New research on Oncology - Prostate Cancer is the subject of a report. According to news originating from Florence, Italy, by NewsRx correspondents, research stated, “Prostate cancer is the second most frequent cancer worldwide, with a very high rate of progression despite treatment. The most aggressive form of the disease is known as castration-resistant prostate cancer, which carries a poor prognosis.”

Our news journalists obtained a quote from the research from the University of Florence, “We reviewed available literature regarding the combination of abiraterone acetate antihormonal drug and ablative radiation therapy for the treatment of metastatic castration-resistant prostate cancer. This dual treatment may enhance the effects of second-line hormonal therapy, as radiotherapy renders cancer cells more prone to immune-mediated cytotoxicity. Moreover, radiotherapy exerts its effect both on directly irradiated cells and on other distant tissues, with an abscopal effect, already demonstrated in other solid tumors. This combination treatment is safe and effective, with few adverse events. Moreover, it is of paramount importance in patients with oligoprogression of the primary disease, when current guidelines recommend continuing abiraterone treatment. Ablative radiation therapy is a noninvasive, nontoxic treatment with very high efficacy on local tumor growth control.”

According to the news editors, the research concluded: “In the available literature, the combination of radiation therapy and abiraterone acetate has prolonged both overall survival and progression-free survival, with a positive impact also on locoregional recurrence and distant metastases.”

For more information on this research see: Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence. Tumori Journal, 2019;():030089161983928.

The news correspondents report that additional information may be obtained from L. Livi, 1 Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Largo Brambilla n3, 50134, Florence, Italy. Additional authors for this research include B. Detti, G. Francolini, F. Terziani, L. Triggiani, R.M. D’Angelillo and G. Ingrosso.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1177/0300891619839282. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

Southern Europe
Italy
Europe
Firenze (Florence)
Florence

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Radiation Therapy